FDA · 新闻稿·· 2026-10-16精选AI 评分70
FDA批准罗氏Enspryng用于甲状腺眼病,为可居家皮下注射的IL-6R抑制剂
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) - Yahoo Finance
AI 导读
FDA批准罗氏Enspryng(IL-6R抑制剂)用于甲状腺眼病(TED),成为该适应症首个且唯一可居家皮下注射的治疗选择。Enspryng为first-in-class的IL-6R抑制剂。
来源:FDA · 新闻稿 · news.google.com